Ocular Therapeutix

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell OCUL and other ETFs, options, and stocks.

About OCUL

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC.

CEO

Pravin U. Dugel

CEOPravin U. Dugel

Employees

274

Employees274

Headquarters

Bedford, Massachusetts

HeadquartersBedford, Massachusetts

Founded

2006

Founded2006

Employees

274

Employees274

OCUL Key Statistics

Market cap

1.30B

Market cap1.30B

Price-Earnings ratio

-7.08

Price-Earnings ratio-7.08

Dividend yield

—

Dividend yield—

Average volume

3.19M

Average volume3.19M

High today

$8.41

High today$8.41

Low today

$8.03

Low today$8.03

Open price

$8.40

Open price$8.40

Volume

1.59M

Volume1.59M

52 Week high

$11.78

52 Week high$11.78

52 Week low

$5.79

52 Week low$5.79

Analyst ratings

100%

of 13 ratings

Buy

100%

Hold

Sell

People also own

Based on the portfolios of people who own OCUL. This list is generated using Robinhood data, and it’s not a recommendation.

Ocular Therapeutix

Why Robinhood?

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. Show more

OCUL Key Statistics

Analyst ratings

100%

People also own

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC.